3D 2HG mapping as biomarker for IDH-mutation in glioma

3D 2HG mapping as biomarker for IDH-mutation in glioma - KLI 646

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013218

Enrollment

Registered

2017-11-02

Start date

2019-05-09

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma with IDH1&2 mutations C71

Interventions

Group 1: 7 T MRSI measurement of 2 HG Group 2: 3 T MRSI measurement of 2 HG Group 3: histopathological determination of IDH mutation status

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: WHO grade II and III glioma according to the updated 2016 WHO classification and a Karnofsky performance status =60%

Exclusion criteria

Exclusion criteria: contraindications for MR imaging (claustrophobia, metal implants…), pregnancy

Design outcomes

Primary

Measure	Time frame
Sensitivity und specitivity of the developed MRSI methods for the measurement of 2HG and IDH status in comparison between 3 T and 7 T and to the histopathological gold standard.	—

Secondary

Measure	Time frame
Measurement of 2HG-concentrations during treatment at 3 T and 7 T (at least once within 6 months after glioma resection)	—

Countries

Austria

Contacts

Public ContactGilbert Hangel

Medizinische Universität Wien - Exzellenzzentrum für Hochfeld-MR

gilbert.hangel@meduniwien.ac.at+4314040064710

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026